Edition:
United States

Key Developments: Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

39.30USD
27 May 2016
Change (% chg)

$0.41 (+1.05%)
Prev Close
$38.89
Open
$39.00
Day's High
$39.40
Day's Low
$38.93
Volume
2,912,140
Avg. Vol
2,113,040
52-wk High
$51.72
52-wk Low
$36.00

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories' Abbott Healthcare tangles with regulators over Indian cough syrup complaint - Reuters
Saturday, 12 Sep 2015 08:00pm EDT 

Abbott Laboratories:Abbott Healthcare is challenging an Indian state's accusation that a sample of the company's cough syrup contained excessive levels of codeine, the second multinational to question India's regulatory testing regime in recent months - Reuters.Whether the sample of Abbott's popular "Phensedyl" was a genuine product or a fake has not been established, but the suspect batch of 80,000 bottles has not been recalled - Reuters.Abbott Healthcare is a unit of U.S.-based Abbott Laboratories - Reuters.The excessive codeine, an opium derivative, would violate Indian drugs law - Reuters.  Full Article

Abbott Completes Acquisition of Tendyne Holdings, Inc
Wednesday, 2 Sep 2015 09:00am EDT 

Abbott:Completed its acquisition of Tendyne Holdings, Inc., private medical device company focused on developing minimally invasive mitral valve replacement therapies.Abbott acquired the equity of Tendyne that it did not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future payments tied to regulatory milestones.  Full Article

Abbott Laboratories announces positive results of its naturally dissolving stent from absorb japan study
Tuesday, 1 Sep 2015 04:00am EDT 

Abbott Laboratories:Announces positive one year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorbheart stent to XIENCE, Abbott's permanent drug eluting stent.The trial was conducted in 38 sites in Japan and enrolled 400 people with coronary artery disease, the most common form of heart disease.  Full Article

Abbott Laboratories declares dividend
Wednesday, 22 Jul 2015 08:07am EDT 

Abbott Laboratories:On June 12, 2015, directors declared company's quarterly dividend of $0.24 per share.Abbott's cash dividend is payable on Aug. 15 to shareholders of record at close of business on July 15.  Full Article

Abbott Laboratories reaffirms FY 2015 EPS guidance
Wednesday, 22 Jul 2015 07:45am EDT 

Abbott Laboratories:Says that FY 2015 guidance range for earnings per share (EPS) from continuing operations, excluding specified items, remains unchanged at $2.10 to $2.20.Says that including net specified items, projected earnings per share from continuing operations under GAAP would be $1.50 to $1.60 for FY 2015.FY 2015 EPS of $2.16 - Thomson Reuters I/B/E/S.  Full Article

Abbott Laboratories declares quarterly dividend
Friday, 12 Jun 2015 10:28am EDT 

Abbott Laboratories:Declares quarterly common dividend of 24 cents per share.Payable on Aug. 15.Record date as on July 15.  Full Article

Abbott Laboratories reaffirms FY 2015 EPS guidance
Wednesday, 22 Apr 2015 07:52am EDT 

Abbott Laboratories:Reaffirms FY 2015 EPS from continuing operations, excluding specified items, to remain unchanged at $2.10 to $2.20.Continues to forecast net specified items related to continuing operations for FY 2015 of about $0.77 per share.Including net specified items, projects EPS from continuing operations under U.S. Generally Accepted Accounting Principles (GAAP) to be $1.33 to $1.43 for FY 2015.FY 2015 EPS of $2.14 - Thomson Reuters I/B/E/S.  Full Article

Abbott Laboratories declares quarterly dividend
Wednesday, 22 Apr 2015 07:52am EDT 

Abbott Laboratories:Declared quarterly dividend of $0.24 per share.Dividend is payable on May 15, to shareholders of record at the close of business on April 15.  Full Article

Abbott Laboratories and Sekisui collaborate to offer coagulation testing for laboratories worldwide
Tuesday, 14 Apr 2015 09:00am EDT 

Abbott Laboratories:Says an agreement to offer coagulation testing solutions for laboratories worldwide.Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots.Under agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in United States, Europe and other regions that recognize CE Mark.  Full Article

Mylan NV announces pricing of secondary public offering of portion of Abbott Laboratories' ordinary shares
Tuesday, 31 Mar 2015 07:47pm EDT 

Mylan NV:Says pricing of underwritten public offering of 35,000,000 ordinary shares held by certain subsidiaries of Abbott Laboratories, at $58.35 per share.Says that it has also granted underwriters an option to purchase additional 5,250,000 ordinary shares.Net proceeds from offering will be about $1.99 billion (or $2.29 billion if the option is exercised) after estimated underwriting discounts, commissions and offering expenses.Mylan will not sell any ordinary shares in offering and will not receive any of the proceeds from offering.5,000,000 ordinary shares being sold (or 40,250,000 ordinary shares if underwriters' option is exercised) represent 31.8 pct. or (36.6 pct. if the option is exercised) of the 110,000,000 ordinary shares currently owned by Abbott.Morgan Stanley & Co. LLC and Goldman, Sachs & Co. are acting as joint book-running managers for offering.  Full Article

BRIEF-Slate Retail REIT to acquire Abbott's village in Georgia

* Slate Retail REIT announces the purchase of Abbott's village in Georgia